The short answer
Minivelle is an estradiol-only transdermal patch replaced twice weekly. Its current label approves it for moderate-to-severe hot flashes due to menopause and for prevention of postmenopausal osteoporosis. It comes in 0.025, 0.0375, 0.05, 0.075, and 0.1 mg per day strengths. Unlike Climara and Dotti, vaginal atrophy is not a listed indication on the Minivelle label. People with a uterus usually also need a progestogen.
Boxed warning on the current Minivelle label
The current Minivelle label (DailyMed, July 2026) carries a boxed warning for endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer. In November 2025 the FDA asked hormone therapy manufacturers to remove some boxed-warning language, but a product's warning changes only when its own label is revised.
Contraindications on the label include undiagnosed abnormal genital bleeding, current or past breast cancer, estrogen-dependent cancer, current or past blood clots, current or past stroke or heart attack, liver disease, known blood-clotting disorders, serious allergic reaction to the product, and pregnancy.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Minivelle (estradiol) patch | 2026-07-31 | Endometrial cancer, cardiovascular disorders, probable dementia, breast cancer |
Established evidence
FDA-approved uses
- Moderate-to-severe vasomotor symptoms due to menopause
- Prevention of postmenopausal osteoporosis (non-estrogen medicines should be considered first when this is the only goal)
Minivelle vs other twice-weekly patches
All three deliver estradiol through the skin on the same schedule. A pharmacist or prescriber can confirm whether a substitution is appropriate, because labeled uses and patch designs differ.
| Patch | Schedule | Labeled uses |
|---|---|---|
| Minivelle | Twice weekly | Hot flashes; osteoporosis prevention |
| Dotti | Twice weekly | Hot flashes; vaginal atrophy; plus other labeled uses |
| Vivelle-Dot | Twice weekly | Hot flashes; vaginal atrophy; plus other labeled uses |
Applying the patch
Apply to clean, dry skin of the lower abdomen or buttocks, not the breasts, rotating sites. Replace every three to four days on the same two days each week. Discard used patches folded, away from children and pets.
Established evidence
If you still have a uterus
The label says a progestogen should generally be added for people with a uterus to reduce endometrial cancer risk.
Established evidence
Common side effects
- Application-site irritation
- Breast tenderness
- Headache
- Spotting or bleeding
- Nausea
Questions to ask a healthcare professional
- Is Minivelle right if I also have vaginal symptoms?
- What strength should I start with?
- Which progestogen should I use?
Questions, answered
What people ask about Minivelle
Is Minivelle the same as Vivelle-Dot?+
Both are twice-weekly estradiol patches, but they are separate products with different labeled indications.
Does Minivelle have a boxed warning?+
Yes. As of October 2026 its current label still carries the older boxed warning.
Does Kindr Health offer Minivelle?+
This page is educational and does not state or imply availability through Kindr Health.
Kindr Health does not claim to offer Minivelle on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn how Kindr Health care pathways work. An educational page is not a statement that this medication is available or appropriate for you.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Minivelle (estradiol transdermal system) prescribing information (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c5c47ab-28ee-11e1-bfc2-0800200c9a66
- FDA initiates removal of boxed warnings from menopausal hormone therapy products (2025) — U.S. Department of Health and Human Services / FDA. www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html
- FDA approves labeling changes to menopausal hormone therapy products (first six labels) (2026) — U.S. Food and Drug Administration. www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- The 2022 hormone therapy position statement of The North American Menopause Society (2022) — The Menopause Society (Menopause journal). pubmed.ncbi.nlm.nih.gov/35797481
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.